Price
$0.09
Increased by +1.33%
Dollar volume (20D)
10.40 K
ADR%
12.56
Earnings report date
Aug 8, 2024
Shares float
27.54 M
Shares short
272.73 K [0.99%]
Shares outstanding
38.44 M
Market cap
3.62 M
Beta
1.03
Price/earnings
N/A
20D range
0.07 0.10
50D range
0.07 0.10
200D range
0.05 0.66

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.

Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria.

Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria.

The company was incorporated in 2010 and is based in San Carlos, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 14, 23 -0.39
Increased by +35.00%
-0.38
Decreased by -2.63%
Aug 10, 23 -0.49
Increased by +31.94%
-0.57
Increased by +14.04%
May 10, 23 -0.54
Increased by +16.92%
-0.56
Increased by +3.57%
Mar 29, 23 -0.53
Increased by +32.91%
-0.59
Increased by +10.17%
Nov 10, 22 -0.60
Increased by +18.92%
-0.73
Increased by +17.81%
Aug 8, 22 -0.72
Increased by 0.00%
-0.71
Decreased by -1.41%
May 11, 22 -0.65
Increased by +7.14%
-0.78
Increased by +16.67%
Mar 3, 22 -0.79
Decreased by -25.40%
-0.75
Decreased by -5.33%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 80.00 K
Increased by +N/A%
-36.22 M
Decreased by -55.48%
Decreased by -45.27 K%
Decreased by N/A%
Jun 30, 23 71.00 K
Increased by +N/A%
-19.19 M
Increased by +31.55%
Decreased by -27.02 K%
Decreased by N/A%
Mar 31, 23 92.00 K
Increased by +N/A%
-18.76 M
Increased by +24.72%
Decreased by -20.39 K%
Decreased by N/A%
Dec 31, 22 20.00 K
Increased by +N/A%
-20.91 M
Increased by +29.14%
Decreased by -104.58 K%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-23.29 M
Increased by +14.86%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-28.03 M
Decreased by -5.08%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-24.92 M
Increased by +3.32%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-29.52 M
Decreased by -28.30%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY